On the commercialization side, Amylyx has been reporting some mixed results since the approval of this ALS drug. Branded as Albrioza in Canada and as Relyvrio in the US, sales of the drug have brought in $272.3 million in the first three full quarters since the US approval and launch. Product revenue in 3Q23, the last reported, came to $102.7 million. That quarterly total, however, missed the forecast by $10.96 million.